Concentrations and in vivo antibacterial activity of spiramycin and metronidazole in patients with periodontitis treated with high-dose metronidazole and the spiramycin/metronidazole combination.
OBJECTIVE
Previous studies have shown that metronidazole, alone or in combination with spiramycin (250 mg/1 500 000 units, three times/day), is an effective treatment for active periodontitis, although the dose of metronidazole currently used (750 mg/day) could provide concentrations in gingival crevice fluid that are too low for the MICs of the involved pathogens. This study tested the in vivo antibacterial efficacy of the currently used metronidazole dose (as contained in the fixed spiramycin/metronidazole combination) in patients with an active periodontitis, and of a high dose (1500 mg/day) of metronidazole alone.


METHODS
We measured the MICs of spiramycin and metronidazole for the recovered pathogens and the gingival crevice fluid antibiotic concentrations of both antibiotics, and attempted to correlate them with bacterial eradication.


RESULTS
The concentrations of metronidazole consistently exceeded the MICs for the pathogens isolated in the corresponding sites, even at the usual metronidazole (250 mg three times/day) dose. All the bacterial species were eradicated during treatment and at follow-up, although Fusobacterium spp. eradicated during treatment reappeared in a majority of the cases at follow-up, 30 days after treatment, in both groups.


CONCLUSIONS
The results of antibiotic therapy with metronidazole or the spiramycin/metronidazole combination are consistent with their in vitro antibacterial activity and with the local antibiotic concentrations; they suggest that the currently used metronidazole dose (250 mg, three times/day) alone or as part of the spiramycin/metronidazole combination, could be sufficient for the treatment of active periodontitis.
Poulet
Pierre-Pascal
PP
Laboratory of Oral Biology, School of Dental Medicine, Toulouse, France.
Duffaut
Danielle
D
Barthet
Pierre
P
Brumpt
Ivan
I
D004359:Drug Therapy, Combination; D005883:Gingival Crevicular Fluid / Q000378:metabolism; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010518:Periodontitis / Q000188:drug therapy*; D011446:Prospective Studies; D015572:Spiramycin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology
D008795:Metronidazole; D015572:Spiramycin